Genetic Technologies (GTG.AX) Osake Kurssi

Genetic Technologies Ltd is primarily active in the biotechnology and healthcare industries.

The main competitors of Genetic Technologies Ltd in the market include companies such as Myriad Genetics Inc., Quest Diagnostics Incorporated, and Illumina Inc. These companies operate within the genetic testing and diagnostics industry, offering similar products and services. However, Genetic Technologies Ltd distinguishes itself by leveraging its innovative technology and expertise to provide unique solutions in the field of genetic testing. As a leading player in this market, Genetic Technologies Ltd continuously strives to maintain its competitive edge through research and development, strategic partnerships, and expanding its product portfolio to cater to the growing demands and challenges of the industry.

Genetic Technologies Ltd is a renowned biotechnology company specializing in genetic testing and analysis. Established in 1989, the company has a rich history of over three decades in the field. Genetic Technologies has emerged as a leader in developing and commercializing innovative gene-based solutions for various industries, including healthcare, agriculture, and forensic sciences. With a strong focus on genetic research, the company has garnered international recognition for its expertise in DNA analysis, genotyping, and molecular diagnostics. Genetic Technologies Ltd continues to pioneer advancements in genetic science, empowering individuals and businesses with valuable genetic insights and solutions.

Genetic Technologies Ltd, a leading biotechnology company, has achieved numerous significant milestones throughout its journey. The company has successfully developed innovative genetic testing solutions, positioning itself as a pioneer in the field. Genetic Technologies Ltd has gained recognition for its breakthrough research and development, resulting in the development of commercially viable products. Additionally, the company has formed strategic partnerships, expanding its reach and enhancing its market presence. With its dedication to advancing genetic technologies, Genetic Technologies Ltd has secured valuable patents and intellectual property rights, further solidifying its position as a key player in the industry. Overall, Genetic Technologies Ltd has a proven track record of accomplishments, making it a compelling choice for investors seeking growth opportunities in the biotech sector.

Genetic Technologies Ltd is primarily present in Australia, where it is headquartered. The company operates in multiple regions within Australia, including Victoria and Queensland. As a global provider of molecular risk assessment tools, Genetic Technologies also has a presence in the United States. With an aim to improve healthcare through innovative genetic testing solutions, Genetic Technologies Ltd continues to expand its reach and strive for advancements in the field of genomics.

Genetic Technologies Ltd represents a commitment to genetic research and innovation in the field of personalized medicine. The company's core values include integrity, scientific excellence, and a strong focus on patient care. With a vision to enhance healthcare outcomes through genetic testing, Genetic Technologies aims to provide cutting-edge solutions to assist healthcare providers and empower individuals in making informed decisions about their health. By leveraging advanced technologies and partnerships, Genetic Technologies demonstrates a corporate philosophy centered on driving advancements in genomics and improving the quality of global healthcare.

Nykyisellä valuuttakurssilla Genetic Technologies-osake noteerataan hintaan 0,02 EUR (0,04 AUD).

Genetic Technologies-osake (GTG.AX) on listattuna 3 pörssissä, muun muassa: ASX (GTG.AX), Frankfurt (DU8.F).

Genetic Technologies Ltd is an international company specializing in the development of genetic tests and diagnostic kits. It was founded in 1989 and is headquartered in Melbourne, Australia. The company has become a leading provider in personalized medicine and genetic analysis. They offer a wide range of genetic tests for various conditions such as cancer, cardiovascular diseases, osteoporosis, and neurological disorders. They also provide diagnostic kits that are easy to use and provide quick results, making the treatment process easier for patients. Additionally, they engage in research and development to expand their portfolio of medical solutions. The company holds patents in the field of genetic analysis and licenses its technologies to other organizations. Some of their products include BRCA tests for identifying genetic mutations associated with breast and ovarian cancer, BREVAGenplus for assessing an individual's risk of developing breast cancer, CardioID for determining a person's risk of cardiovascular diseases, and COVID-19 tests for diagnosing coronavirus infections. With their innovative solutions in personalized medicine and genetic analysis, Genetic Technologies Ltd continuously expands its existing business areas and actively seeks new opportunities.

odotettu liikevaihto Genetic Technologies on 28,60 M AUD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

Voittoa ei voida laskea Genetic Technologies:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Genetic Technologies:lle tällä hetkellä.

Genetic Technologies:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,20. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Genetic Technologies-osakkeen arvostuskennuslukuna.

Genetic Technologies:n Eulpool-laatuscore on 2/10.

Genetic Technologies:n ISIN on AU000000GTG7. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Genetic Technologies:n WKN on 893882. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Genetic Technologies:n ticker on GTG.AX. Tämä pörssinoteeraus käytetään Genetic Technologies-osakkeiden kauppaan pörssissä.